Anti-talen antibodies and uses thereof
OwnerThomas Charles PERTEL, Barbra Johnson SASUinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.
Claims42
An anti-TALEN antibody comprising a variable heavy chain amino acid sequence that is at least 85% identical to SEQ ID NO:
- 3 and a variable light chain amino acid sequence that is at least 85% identical to SEQ ID NO:
- 7.
The anti-TALEN antibody of any one of the preceding claims, comprising a heavy chain CDR1 selected from the group consisting of SEQ ID NOs:
- 12-14.
The anti-TALEN antibody of any one of the preceding claims, comprising a heavy chain CDR2 selected from the group consisting of SEQ ID NOs:
- 15-20.
The anti-TALEN antibody of any one of the preceding claims, comprising a heavy chain CDR3 comprising SEQ ID NO:
- 21.
The anti-TALEN antibody of any one of the preceding claims, wherein the heavy chain comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3, each CDR comprising an amino acid sequence shown in Table 1c.
An anti-TALEN antibody, comprising
- (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:12;
- (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
- 15;
- (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
- 23;
- and
- (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
- 26.
An anti-TALEN antibody, comprising
- (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:
- 12;
- (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
- 16;
- (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
- 24;
- and
- (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
- 27.
An anti-TALEN antibody, comprising
- (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:
- 13;
- (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
- 16;
- (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
- 25;
- and
- (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
- 26.
An anti-TALEN antibody, comprising
- (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:
- 12;
- (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
- 15;
- (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
- 24;
- and
- (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
- 28.
An anti-TALEN antibody, comprising
- (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:
- 12;
- (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
- 17;
- (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
- 24;
- and
- (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
- 27.
An anti-TALEN antibody, comprising
- (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:
- 12;
- (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
- 15;
- (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
- 24;
- and
- (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
- 27.
An anti-TALEN antibody, comprising
- (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:
- 12;
- (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
- 16;
- (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
- 25;
- and
- (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
- 26.
A vector comprising the polynucleotide of claim 35 or claim 36. 38. A cell comprising one or both of the vectors of claim 37.
The cell of claim 38, wherein the cell comprises a cell selected from the group consisting of a CHO cell, a Sp2/0 cell, a rabbit cell and an E. coli cell.
A method of determining the presence or absence of a TALEN protein in a sample, comprising contacting the sample with an anti-TALEN antibody conjugated to a detectable label and determining the presence or absence of the TALEN protein in the sample.
Dependencies are inferred from the claim text.